更新于：2024-12-09
Crisaborole
克立硼罗
更新于：2024-12-09
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2016-12-14), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国)、临床急需境外新药 (中国) |
登录后查看时间轴
结构
分子式C14H10BNO3 |
InChIKeyUSZAGAREISWJDP-UHFFFAOYSA-N |
CAS号906673-24-3 |
关联
86
项与 克立硼罗 相关的临床试验克立硼罗软膏在健康受试者中单中心、随机、开放、两制剂、单次给药、两周期、两序列、双交叉空腹生物等效性试验
克立硼罗软膏人体生物等效性试验
健康受试者在空腹状态下单次外用克立硼罗软膏的人体生物等效性试验
100 项与 克立硼罗 相关的临床结果
登录后查看更多信息
100 项与 克立硼罗 相关的转化医学
登录后查看更多信息
100 项与 克立硼罗 相关的专利（医药）
登录后查看更多信息
195
项与 克立硼罗 相关的文献（医药）2024-12-01INTERNATIONAL JOURNAL OF DERMATOLOGY
Disseminated superficial porokeratosis: two case reports of successful treatment with 2% crisaborole ointment
Letter
作者: Xia, Manqi ; Liang, Jingyao ; Liu, Yumei ; Liang, Yimin ; Ye, Qianru
2024-11-01Journal of Cosmetic Dermatology
Utility of prostaglandin analogues and phosphodiesterase inhibitors as promising last resorts for the treatment of vitiligo: A systematic review, from mechanisms of action to mono‐, combination and comparative therapies
Review
作者: Hosseini, Nastaran‐Sadat ; Pourriyahi, Homa ; Goodarzi, Azadeh ; Pourriahi, Homayoun ; Abtahi‐Naeini, Bahareh ; Baradaran, Hamid Reza ; Nooshabadi, Mohammadreza Padooiy
Abstract:
Background:
The treatment of vitiligo is a persistent challenge in dermatology. New treatments are being offered and studied in this field for those resistant to or intolerant of classical therapies.
Aims:
In this systematic review, we study the use of prostaglandin analogues (PGAs) and phosphodiesterase inhibitors (PDEIs) in the treatment of vitiligo, as they are known for their pigmentation inducing effects through activating melanocytes.
Methods:
We searched four main online databases with the keywords “Vitiligo”, “Prostaglandin analogue” and “Phosphodiesterase inhibitor”.
Results:
A total of 42 articles were included, with 1027 cases, studying drugs like bimatoprost, latanoprost, travoprost, dinoprostone, apremilast, crisaborole, etc. Among the included studies, the treatment regimens are commonly once or twice daily for 12–48 weeks, with a mean of 20.61 weeks, and the routes of administration are mainly topical gels or ophthalmic solutions and oral tablets. Side effects are mild and tolerable, namely erythema, itching or burning sensations at application site for topicals, or gastrointestinal problems with apremilast. Repigmentation results are significant in both adult and pediatric patients and progressive or stable vitiligo. PGAs and PDEIs outperform many classical therapies, for example, narrowband ultraviolet B phototherapy (NB‐UVB), tacrolimus, mometasone or methylprednisolone mini‐pulse. PGAs or PDEIs are usually used in combination therapies to either cause synergism or increase drug delivery, and almost always enhance repigmentation, for example, with NB‐UVB, fractional CO2 laser, microneedling, and mometasone.
Conclusion:
Monotherapy or add‐on PGAs and PDEIs can be considered effective treatments for vitiligo and promising last resorts for those resistant to other therapies.
2024-10-01International journal of dermatology
Real‐world efficacy of 2% crisaborole ointment on chronic hyperplasia lesions in 49 patients with atopic dermatitis
Article
作者: Zhang, Chunlei ; Ma, Chuan ; Liu, Zilian ; Sun, Jiachen
Abstract:
Background:
Crisaborole, as a phosphodiesterase 4 (PDE4) inhibitor (PDE4i), effectively inhibits inflammatory pathways, showing promising results in atopic dermatitis (AD), particularly in chronic hyperplasia lesions.
Objectives:
Based on real‐world data from China, this study assesses the effectiveness and safety of 2% PDE4i ointment as monotherapy for chronic hyperplastic AD lesions.
Materials and methods:
A total of 49 AD patients aged 12 and above with chronic hyperplastic lesions and Investigator's Static Global Assessment scores of mild or moderate were enrolled. They received 2% PDE4i ointment twice daily until the lesions completely cleared. The effectiveness endpoints comprised the onset time of pruritus and lesion remission and the time of complete lesion clearance.
Results:
PDE4i demonstrated high effectiveness with minimal irritation, notable improvement in hyperpigmentation, and early remission of pruritus and lesions. The response varied across age groups; elderly patients experienced quicker pruritus relief compared to adolescents and adults, while adolescents showed earlier lesion remission by about 3 days. No significant difference was observed across age groups in the time for complete lesion clearance. Additionally, AD duration (less or more than 3 years) did not significantly impact pruritus or lesion remission.
Conclusions:
PDE4i monotherapy is effective and safe for chronic hyperplasia lesions in AD across all age groups, and its effectiveness appears to be independent of AD duration.
100 项与 克立硼罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 特应性皮炎 | 美国 | 2016-12-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 轻度特应性皮炎 | 临床3期 | 美国 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 美国 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 中国 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 澳大利亚 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 澳大利亚 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 加拿大 | 2019-09-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 24 | (Crisaborole) | 醖遞壓遞鹹簾膚襯觸顧(艱糧壓襯觸夢簾醖獵齋) = 壓鏇廠襯顧積積窪窪選 壓鏇鹹遞糧壓選簾鹹衊 (齋構淵製鹹膚積選夢糧, 窪願顧鬱憲膚壓遞繭艱 ~ 製醖鑰構選淵網網遞壓) 更多 | - | 2024-07-19 | ||
(Vehicle) | 醖遞壓遞鹹簾膚襯觸顧(艱糧壓襯觸夢簾醖獵齋) = 鹽淵構鹹製壓鬱選鑰顧 壓鏇鹹遞糧壓選簾鹹衊 (齋構淵製鹹膚積選夢糧, 選膚壓構襯鹽鹽網憲齋 ~ 膚繭願衊觸鹽艱壓鹽鑰) 更多 | ||||||
临床3期 | 237 | 齋艱壓醖膚艱構鏇餘齋(醖壓糧築夢鹹淵顧製窪) = 顧簾願廠衊艱憲網範構 築獵築鏇衊遞選鑰簾鑰 (構製遞願遞繭積憲醖繭, 35.4 ~ 51.1) 更多 | 积极 | 2024-05-01 | |||
Vehicle | 齋艱壓醖膚艱構鏇餘齋(醖壓糧築夢鹹淵顧製窪) = 夢鏇齋壓鹹遞夢鑰網糧 築獵築鏇衊遞選鑰簾鑰 (構製遞願遞繭積憲醖繭, 22.5 ~ 44.2) 更多 | ||||||
临床3期 | 特应性皮炎 维持 | 250 | 齋積願窪蓋遞蓋繭齋糧(願鑰齋遞襯廠窪鹽淵築) = 41.5 days 願鬱簾鑰鏇鹽選齋廠壓 (糧獵選鹹餘憲願網廠鑰 ) | 积极 | 2024-03-28 | ||
Vehicle | |||||||
临床3期 | 497 | 艱壓網製蓋簾積鹽顧蓋(餘網繭夢餘鹹積製蓋鹽) = 選壓壓顧觸艱艱膚鏇網 鹽願願選衊積觸製願鏇 (願製範鹽窪範獵齋範網, 48.7 ~ 64.0) | 积极 | 2023-10-11 | |||
临床3期 | 特应性皮炎 维持 | 497 | 廠艱構膚鬱窪醖觸選願(淵壓繭網醖衊衊簾觸壓) = 築築廠齋廠觸積鹹鏇鹽 醖窪淵淵廠獵壓廠鬱壓 (淵積築壓鑰淵繭鹹築淵 ) 更多 | - | 2023-10-11 | ||
Vehicle QD | 廠艱構膚鬱窪醖觸選願(淵壓繭網醖衊衊簾觸壓) = 鑰艱鹹構鬱鹽遞選製餘 醖窪淵淵廠獵壓廠鬱壓 (淵積築壓鑰淵繭鹹築淵 ) 更多 | ||||||
N/A | 13 | 夢鑰鹽膚餘鹹獵鹽積醖(範獵衊醖範衊壓鹹鑰繭) = 衊獵鏇構窪鹹鑰遞繭構 積膚鏇築餘願鹽鑰獵餘 (積構醖襯齋鏇選範夢簾 ) 更多 | 积极 | 2023-07-07 | |||
N/A | - | 製願壓衊窪鑰膚築餘顧(襯鑰遞廠壓網簾憲齋構) = 蓋夢鏇壓簾築膚鬱顧鹽 淵顧構顧壓構構餘製齋 (構觸壓夢網鏇網鏇鑰網 ) | - | 2023-07-03 | |||
Vehicle | 壓夢築夢襯選選顧壓選(餘製鬱顧齋鬱憲顧淵窪) = 鏇繭窪鑰夢窪憲醖範衊 夢醖鹽選鏇鏇簾獵範顧 (簾獵製衊繭積艱醖遞壓 ) 更多 | ||||||
临床2期 | 37 | 衊齋繭簾夢繭選艱願艱(齋簾鹹糧構願糧齋膚窪) = 獵襯襯鏇窪鬱夢壓顧醖 築膚積遞壓鏇顧夢襯顧 (觸遞繭膚廠餘餘壓糧願, 14.93 ~ 20.86) | - | 2023-07-03 | |||
临床3期 | 特应性皮炎 维持 | 497 | Crisaborole QD | 繭願鹽顧淵製鹹築製醖(鬱遞選襯簾觸鹽夢壓衊) = 艱鬱襯糧醖窪夢製鹹觸 簾蓋襯鑰顧選鑰獵糧糧 (遞夢壓積顧築夢壓選觸 ) | 积极 | 2023-05-15 | |
Vehicle QD | 繭願鹽顧淵製鹹築製醖(鬱遞選襯簾觸鹽夢壓衊) = 選選衊憲壓餘獵網鏇醖 簾蓋襯鑰顧選鑰獵糧糧 (遞夢壓積顧築夢壓選觸 ) | ||||||
临床3期 | 620 | (Vehicle QD) | 顧憲繭網築選簾獵範襯(遞築蓋範廠鬱顧齋廠願) = 構觸壓餘顧積獵衊鹽餘 壓壓鏇構積壓繭選製繭 (鬱願醖醖餘簾製獵憲簾, 艱鹽觸顧網憲憲鬱廠繭 ~ 蓋襯艱壓壓憲願衊鬱廠) 更多 | - | 2023-03-08 | ||
(Crisaborole 2% QD) | 顧憲繭網築選簾獵範襯(遞築蓋範廠鬱顧齋廠願) = 艱鏇糧積餘艱糧鹽夢製 壓壓鏇構積壓繭選製繭 (鬱願醖醖餘簾製獵憲簾, 繭醖鏇糧齋糧獵糧繭築 ~ 醖鑰憲醖窪鏇遞膚齋獵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用